earnings reports

J&J raises revenue forecast, estimates $2.5 billion in COVID-19 vaccine sales

Reuters

This is AI generated summarization, which may have errors. For context, always refer to the full article.

J&J raises revenue forecast, estimates $2.5 billion in COVID-19 vaccine sales

J&J. Vials and a medical syringe are seen in front of a displayed Johnson & Johnson logo in this illustration taken October 31, 2020.

Dado Ruvic/Reuters

Johnson & Johnson's vaccine sales outlook still pales in comparison with its peers and reflects the widening gap in the global vaccine race

Johnson & Johnson raised its 2021 revenue estimates on Wednesday, July 21, and forecast it would sell $2.5 billion worth of its COVID-19 vaccine this year, as it strives to quell production and safety problems and catch up with rivals Pfizer and Moderna.

Although Johnson & Johnson’s single-dose shot was approved in the United States months after shots from Pfizer and Moderna were cleared, its vaccine sales outlook still pales in comparison with its peers and reflects the widening gap in the global vaccine race.

Pfizer and Moderna have forecast $26 billion and $19.2 billion in annual sales of their vaccines, respectively.

The J&J vaccine, once touted as an important tool for vaccinations in hard-to-reach areas, has the least uptake in Europe among all the vaccines approved for use, and has also struggled in the United States.

J&J expects to produce 500 million to 600 million doses of the vaccine this year, chief financial officer Joseph Wolk told CNBC on Wednesday.

J&J raised its expectations for full-year sales, encouraged by a recovery in sales at its medical devices unit and higher demand for treatments such as psoriasis and Crohn’s disease drug Stelara.

Sales at the company’s medical devices unit rose 62.7% to $6.98 billion, boosting its second-quarter numbers.

The company now expects annual sales in a range of $93.8 billion to $94.6 billion including contribution from the vaccine, and $91.3 billion to $92.1 billion for the rest of the business.

It had previously forecast sales to come in between $90.6 billion and $91.6 billion.

J&J recorded $164 million in sales of its COVID-19 vaccine for the second quarter.

In the second quarter, J&J earned $2.48 per share, beating analysts’ average estimate of $2.27 per share, according to IBES data from Refinitiv.

Shares of the company rose marginally to $169.97 before the opening bell. – Rappler.com

Add a comment

Sort by

There are no comments yet. Add your comment to start the conversation.

Summarize this article with AI

How does this make you feel?

Loading
Download the Rappler App!